MARKETWIRE: The approval of Dendreon’s prostate cancer vaccine Provenge in April was a boon for a nascent cancer vaccine industry that had suffered several setbacks, and should lead to an influx of market opportunities and a surge in regulatory activity. READ MORE>
Posts Tagged ‘Dendreon’
Provenge approval expected to rejuvenate cancer vaccine industry
Posted in Provenge, tagged advanced prostate cancer, cancer research, cancer vaccine industry, catherise, catheter, catheterisation, Dendreon, MARKETWIRE, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, Provenge, Provenge treatment, URO TODAY on September 12, 2010| Leave a Comment »
Prostate cancer drug Provenge finally starts earning money for its maker
Posted in Provenge, tagged advanced prostate cancer, catheter, Dendreon, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, prostate treatment, prostate treatment debate, Provenge, Provenge treatment, WALL ST JOURNAL on August 6, 2010| Leave a Comment »
WALL ST JOURNAL: New wonder drug for treating advanced prostate cancer, Provenge, is finally making money for its manufacturer, Dendreon Corp. READ MORE>
Since the $93,000 treatment was launched at the beginning of May, doctors have written 500 prescriptions for the treatment, the company disclosed.
Provenge extends prostate patients’ lives about four months – at a cost of $130,000
Posted in Provenge, tagged ABC NEWS, advanced prostate cancer, cancer research, catheter, Dendreon, extending life, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, prostate treatment, prostate treatment debate, Provenge, Provenge treatment on July 31, 2010| Leave a Comment »
ABC NEWS: The new US wonder drug for treating advanced prostate cancer – Provenge – extends life about four months – at a cost of $NZ130,000 ($US93,000).
The makers say it took 15 years to develop, at a cost of $US1.2 billion. READ MORE> and MORE>
Alternative business website purports to reveal scandal behind rival to Provenge’s eventual success
Posted in PROSTATE CANCER, Provenge, Treatment news, tagged Dendreon, drug scandal, FDA approval, Larry King Live, Market Rap.com, Michael Milken, Provenge, US Prostate Cancer Foundation, Wall Street Journal on September 6, 2009| Leave a Comment »
PROSTABLOG NZ: When global mainstream media reported the recent (partial) success of Dendreon drug company getting FDA approval for its new immunotherapy prostate cancer drug, Provenge, they didn’t mention how makers of a now-discredited rival drug may have delayed its path to chemist shops.
An “alternative” market investors’ website called Market Rap.com has just published a story by a former Wall Street Journal journalist that purports to reveal a murky background to what might be called – if it’s all, even partly, true – one of America’s biggest drug scandals.
It involves the US prostate Cancer Foundation (no relation to NZ’s) and its ubiquitous chairman, Michael Milken, who featured recently on the Larry King Live special about prostate cancer.
If you’ve got lots of time, READ MORE>
US drug company that will produce Provenge is so far having a bad year
Posted in PROSTATE CANCER, Provenge, Treatment news, tagged advanced prostate cancer, Dendreon, immuno-therapy prostate cancer treatment, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, prostate treatment, prostate treatment debate, Provenge, Provenge treatment, PUGET SOUND BUSINESS JOURNAL on August 13, 2009| Leave a Comment »
PUGET SOUND BUSINESS JOURNAL: The US drug company that is about to produce the world’s most promising immuno-therapy prostate cancer treatment – Provenge – has reported a second-quarter loss of $126.7 million. READ MORE>
PROSTATE FUTURE: New drug will be ready for baby boomers
Posted in Immunotherapy, New prostate drugs, PROSTATE CANCER, Prostate drugs, PROSTATE RESEARCH, Treatment news, tagged advanced prostate cancer, Baby Boomers, cancer research, Dendreon, immunotherapy vaccines, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, prostate treatment, prostate treatment debate, Provenge treatment, U.S. Food and Drug Administration on June 11, 2009| Leave a Comment »
JUNE 11: SEEKING ALPHA.COM: A groundbreaking new treatment for prostate cancer, Provenge, will likely receive US Food and Drug Administration approval and become widely available just as the first Baby Boomers reach 65 in 2010. READ MORE>
